Shopping Cart is Empty..

$ 0

Chinese Patent Medicine Market by Disease Type (Cardiovascular and Cerebrovascular Diseases, Tumor Diseases, Respiratory System Diseases, Musculoskeletal Diseases, and Digestive System Diseases); Dosage Type (Injection, Capsule, Pills, and Syrups); and End User (Hospitals, and Pharmacies or Drugstores) - Opportunities and Industry Forecasts, 2017-2023

Healthcare	LI 173525	Pages: NA	Formats*:
Nov 2017 \| 87 Views	Charts: NA	Tables: NA	Author(s): NA

Chinese patent medicines refer to herbal medicines, mainly extracted condensed pills called teapills, which are usually small, spherical, and black. Patents may come for various types of medicines such as syrups, dripping pills, liquids, capsules, powders, granules, and instant teas, which are manufactured by Chinese companies and exported within and outside China.

The major factors that contribute to the growth of the Chinese patent medicines market include the increasing prevalence of cardiovascular & cerebrovascular diseases, rise in health concerns among people, rising popularity of Chinese patent medicine with less toxicity & fewer side effects, and high demand for traditional Chinese medicine among patients. However, heavy metal contamination and stringent government regulations for prohibited ingredients may restrain the market. The development of drugs with less metal contamination and increasing ageing population presents a major opportunity for the market growth.

The Chinese patent medicines market is segmented on the basis of disease type, dosage forms, end user, and region. Based on disease type, the market is divided into cardiovascular & cerebrovascular diseases, tumor diseases, respiratory system diseases, musculoskeletal diseases, digestive system diseases, and others. On the basis of dosage form the market is segmented into injection, capsule, pills, syrups, and others. According to end user, the market is divided into hospitals, pharmacies or drugstores, and others.

The key players that operate in this market include Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, Yangtze River Pharmaceutical (Group) Co., Ltd., China Resources Pharmaceutical Group Limited, Shanghai Pharmaceutical Co., Ltd., Taiji Group Co., Ltd., Tasly.Phar. International Co., Ltd., Yunnan Baiyao Group Co., Ltd., Zhangzhou Pientzehuang Pharmaceutical Co., Ltd., Shandong Dong-E E-Jiao Co., Ltd., and Tibet Rhodiola Pharmaceutical Holding Co., Ltd.

Key Benefits

The study provides an in-depth analysis of the Chinese patent medicines market with current trends and future estimations to elucidate imminent investment pockets.
The report provides information about the current and upcoming trends in the Chinese patent medicines market from 2016 to 2023, which helps determine prevailing opportunities.
Comprehensive analysis of factors that drive and restrict the growth of the Chinese patent medicines market has been provided.
Identification of factors that are instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a regional scale have been provided.
Key market players within the market have been profiled in this report and their strategies thoroughly analyzed, which help understand the competitive outlook of the Chinese patent medicines market.

Chinese Patent Medicine Market Key Segments:

By Disease Type

Cardiovascular and Cerebrovascular Diseases
Tumor Diseases
Respiratory System Diseases
Musculoskeletal Diseases
Digestive System Diseases
Others

By Dosage Type

Injection
Capsule
Pills
Syrups
Others

By End User

Hospitals
Pharmacies or Drugstores
Others

Enquiry About Report

Please input above shown text into input box
or click refresh

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
Technologically sophisticated and reliable insights through well audited and veracious research methodology
Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

Patent and regulatory databases for understanding of technical & legal developments
Scientific and technical writings for product information and related preemptions
Regional government and statistical databases for macro analysis
Authentic new articles, web-casts and other related releases for market evaluation
Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

Validates and improves the data quality and strengthens research proceeds
Further develops analyst team’s market understanding and expertise
Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

Chief executives and VPs of leading corporations specific to industry
Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

License Type

Data Pack

Single User PDF

Five User Online/PDF

Enterprise Online/PDF

LICENSE INFO

Users/Sharing

Restricted to one authorized user

Limited to 5 authorized users

Unlimited within company / enterprise

Printing

One Print only

Up to Five Copies

Unlimited within company / enterprise

Delivery Formats

ADDED BENIFITS

20% Free customization (Pre-sale)

16 Analyst hour support (Post Sale)

40 Analyst hour support (Post Sale)

160 hours of mini-consult

Free quarterly industry update

Free report on update (within 180 days)

MULTIPLE PURCHASE

Complimentary report with 2 reports

Complimentary report with 3 reports

Subscription Model

Have questions ?
Speak with analyst

Did you miss anything?
To add more

* Taxes/Fees, If applicable, will be
added at the checkout. All prices in USD.

Need More Information

+1-503-894-6022

help@alliedmarketresearch.com

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

Targeted Market View

Targeted market view to eliminate redundant information to provide valued information and save time of the reader

Get fresh content delivered

Get insights on topics that matter to your business. Stay updated on the areas that interest you.

Report Title: Chinese Patent Medicine Market by Disease Type (Cardiovascular and Cerebrovascular Diseases, Tumor Diseases, Respiratory System Diseases, Musculoskeletal Diseases, and Digestive System Diseases); Dosage Type (Injection, Capsule, Pills, and Syrups); and End User (Hospitals, and Pharmacies or Drugstores) - Opportunities and Industry Forecasts, 2017-2023

Select Chapters

Chapter 1 Chapter 2 Chapter 3 Chapter 4 Chapter 5 Chapter 6 Chapter 7

Full Name: *:

Company Name: *:

Job Role: *:

Email: *:

Country: *:

Contact Number: *:

How can we help? *:

Security Code: *:

STAY WITH US

WE ACCEPT

* Pricing on the website is provided for single users licenses only. All reports will be provided in a PDF format for download. To purchase multi-user licenses, please contact us at +1-800-792-5285 or send an email to sales@alliedmarketresearch.com
Chapter: 1 INTRODUCTION 1.1. REPORT DESCRIPTION 1.2. KEY BENEFITS 1.3. KEY MARKET SEGMENTS 1.4. RESEARCH METHODOLOGY 1.4.1. Secondary research 1.4.2. Primary research 1.4.3. Analyst tools & models
Chapter: 2 EXECUTIVE SUMMARY 2.1. CXO PERSPECTIVE
Chapter: 3 MARKET OVERVIEW 3.1. MARKET DEFINITION AND SCOPE 3.2. KEY FINDINGS 3.2.1. Top investment pockets 3.2.2. Top winning strategies 3.3. MARKET SHARE ANALYSIS, 2016 3.4. PORTER’S FIVE FORCES ANALYSIS 3.5. MARKET DYNAMICS 3.5.1. Drivers 3.5.2. Restraints 3.5.3. Opportunities
Chapter: 4 CHINESE PATENT MEDICINE MARKET, BY DISEASE TYPE 4.1. OVERVIEW 4.1.1. Market size and forecast 4.2. CARDIOVASCULAR AND CEREBROVASCULAR DISEASES 4.2.1. Key market trends 4.2.2. Growth factors and opportunities 4.2.3. Market size and forecast 4.3. TUMOR DISEASES 4.3.1. Key market trends 4.3.2. Growth factors and opportunities 4.3.3. Market size and forecast 4.4. RESPIRATORY SYSTEM DISEASES 4.4.1. Key market trends 4.4.2. Growth factors and opportunities 4.4.3. Market size and forecast 4.5. MUSCULOSKELETAL DISEASES 4.5.1. Key market trends 4.5.2. Growth factors and opportunities 4.5.3. Market size and forecast 4.6. DIGESTIVE SYSTEM DISEASES 4.6.1. Key market trends 4.6.2. Growth factors and opportunities 4.6.3. Market size and forecast 4.7. OTHERS 4.7.1. Key market trends 4.7.2. Growth factors and opportunities 4.7.3. Market size and forecast
Chapter: 5 CHINESE PATENT MEDICINE MARKET, BY DOSAGE FORM 5.1. OVERVIEW 5.1.1. Market size and forecast 5.2. INJECTION 5.2.1. Market size and forecast 5.3. CAPSULE 5.3.1. Market size and forecast 5.4. PILLS 5.4.1. Market size and forecast 5.5. SYRUPS 5.5.1. Market size and forecast 5.6. OTHERS 5.6.1. Market size and forecast
Chapter: 6 CHINESE PATENT MEDICINE MARKET, BY END USER 6.1. OVERVIEW 6.1.1. Market size and forecast 6.2. HOSPITALS 6.2.1. Market size and forecast 6.3. PHARMACIES OR DRUGSTORES 6.3.1. Market size and forecast 6.4. OTHERS 6.4.1. Market size and forecast
Chapter: 7 COMPANY PROFILES 7.1. GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS COMPANY LIMITED 7.1.1. Operating business segments 7.1.2. Business performance 7.1.3. Key strategic moves and developments 7.2. YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD. 7.2.1. Operating business segments 7.2.2. Business performance 7.2.3. Key strategic moves and developments 7.3. CHINA RESOURCES PHARMACEUTICAL GROUP LIMITED 7.3.1. Operating business segments 7.3.2. Business performance 7.3.3. Key strategic moves and developments 7.4. SHANGHAI PHARMACEUTICAL CO., LTD. 7.4.1. Operating business segments 7.4.2. Business performance 7.4.3. Key strategic moves and developments 7.5. TAIJI GROUP CO., LTD. 7.5.1. Operating business segments 7.5.2. Business performance 7.5.3. Key strategic moves and developments 7.6. TASLY.PHAR. INTERNATIONAL CO., LTD. 7.6.1. Operating business segments 7.6.2. Business performance 7.6.3. Key strategic moves and developments 7.7. YUNNAN BAIYAO GROUP CO., LTD. 7.7.1. Operating business segments 7.7.2. Business performance 7.7.3. Key strategic moves and developments 7.8. ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL CO., LTD. 7.8.1. Operating business segments 7.8.2. Business performance 7.8.3. Key strategic moves and developments 7.9. SHANDONG DONG-E E-JIAO CO., LTD. 7.9.1. Operating business segments 7.9.2. Business performance 7.9.3. Key strategic moves and developments 7.10. TIBET RHODIOLA PHARMACEUTICAL HOLDING CO., LTD. 7.10.1. Operating business segments 7.10.2. Business performance 7.10.3. Key strategic moves and developments

Purchase Options